Neos Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.33 |
Market Cap |
$71.1 M |
Shares Outstanding |
49.72 M |
Public Float |
42.9 M |
Address |
2940 North Highway 360 Grand Prairie Texas 75050 United States |
Employees | - |
Website | http://www.neostx.com |
Updated | 07/08/2019 |
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. |